Chemical-based epigenetic reprogramming to advance pluripotency and totipotency

被引:0
作者
Wen, Shanshan [1 ]
Zheng, Ran [2 ]
Cai, Cheguo [2 ]
Jiang, Wei [1 ,3 ]
机构
[1] Wuhan Univ, Zhongnan Hosp, Frontier Sci Ctr Immunol & Metab, Med Res Inst,Dept Biol Repositories, Wuhan, Peoples R China
[2] Shenzhen Beike Biotechnol Co Ltd, Shenzhen, Peoples R China
[3] Hubei Prov Key Lab Dev Originated Dis, Wuhan, Peoples R China
基金
中国国家自然科学基金;
关键词
STEM-CELLS; SOMATIC-CELLS; GROUND-STATE; INDUCTION; DERIVATION; DRUG; ESTABLISHMENT; FIBROBLASTS; GENERATION; CIRCUITRY;
D O I
10.1038/s41589-025-01874-8
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Reprogramming technology, breaking the inherent limitations of cellular identity and turning somatic cells into pluripotent cells with more developmental potential, holds great promise for cell therapy and regenerative medicine. Compared with traditional methods based on overexpressing transcription factors, chemical reprogramming with small molecules exhibits substantial advantages in safety and convenience, thus being the leading edge. Over the past decade, a notable focus has been reshaping cellular pluripotency and totipotency using pure small-molecule systems. Here, we provide a concise Review comparing the chemical approaches that have emerged to date and discussing the epigenetic regulatory mechanisms involved in chemical reprogramming. This Review highlights the remarkable potential of small-molecule potions to reformulate cell fate through epigenetic reprogramming and newly discovered actions. We aim to offer insights into chemically controlled cell manipulation and key challenges and future application prospects of chemical reprogramming.
引用
收藏
页码:635 / 647
页数:13
相关论文
共 34 条
  • [31] The RNA-binding protein DND1 acts sequentially as a negative regulator of pluripotency and a positive regulator of epigenetic modifiers required for germ cell reprogramming
    Ruthig, Victor A.
    Friedersdorf, Matthew B.
    Garness, Jason A.
    Munger, Steve C.
    Bunce, Corey
    Keene, Jack D.
    Capel, Blanche
    DEVELOPMENT, 2019, 146 (19):
  • [32] Chemical compound-based direct reprogramming for future clinical applications
    Takeda, Yukimasa
    Harada, Yoshinori
    Yoshikawa, Toshikazu
    Dai, Ping
    BIOSCIENCE REPORTS, 2018, 38
  • [33] CRISPR-Based Chromatin Remodeling of the Endogenous Oct4 or Sox2 Locus Enables Reprogramming to Pluripotency
    Liu, Peng
    Chen, Meng
    Liu, Yanxia
    Qi, Lei S.
    Ding, Sheng
    CELL STEM CELL, 2018, 22 (02) : 252 - +
  • [34] Mass cytometry?based single-cell analysis of human stem cell reprogramming uncovers differential regulation of specific pluripotency markers
    Im, Ilkyun
    Son, Ye Seul
    Jung, Kwang Bo
    Kang, Insoo
    Teh, Boon-Eng
    Lee, Kyung-Bok
    Son, Mi-Young
    Kim, Janghwan
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2019, 294 (49) : 18547 - 18556